<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
September 13, 2000
-------------------------------------------------
(Date of Report: Date of earliest event reported)
IMMUNOTECHNOLOGY CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-24641 84-1016435
---------------------------- ----------------------- --------------------
(State or other jurisdiction (Commission File Number) (IRS Employer ID No.)
of incorporation)
1661 Lakeview Circle, Ogden, Utah 84403
------------------------------------------------
(Address of principal executive office)
Registrant's telephone number, including area code: (801) 399-3632
--------------
Not Applicable
---------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
<PAGE> 2
ITEM 5. OTHER EVENTS
Termination of Negotiations to Acquire Beverly Hills Auctioneers, Inc.
----------------------------------------------------------------------
On May 19, 2000, the Registrant executed a letter of intent to acquire 100% of
the outstanding common stock of Beverly Hills Auctioneers, Inc., Beverly
Hills, California, for newly-issued shares of capital stock of the Registrant.
The acquisition was subject to the negotiation and completion of a definitive
agreement setting forth the terms of the acquisition. On September 13, 2000,
the Registrant announced that negotiations on the definitive agreement and
broken down and no agreement had been reached between the parties.
(c) Exhibits. The following exhibits are included as part of this report:
SEC
Exhibit Reference
Number Number Title of Document Location
------- --------- ----------------- --------
20.03 20 Press Release re: Termination of
Letter of Intent This Filing
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunder duly authorized.
IMMUNOTECHNOLOGY CORPORATION
Date: September 25, 2000 /S/David Knudson, Secretary/Treasurer
